- Home
- CCIR vs TNXP Comparison
CCIR vs TNXP Comparison
Compare CCIR & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIR
- TNXP
- Stock Information
- Founded
- CCIR 2021
- TNXP 2007
- Country
- CCIR United States
- TNXP United States
- Employees
- CCIR N/A
- TNXP N/A
- Industry
- CCIR
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- CCIR
- TNXP Health Care
- Exchange
- CCIR NYSE
- TNXP Nasdaq
- Market Cap
- CCIR 340.2M
- TNXP 365.8M
- IPO Year
- CCIR 2024
- TNXP N/A
- Fundamental
- Price
- CCIR $10.50
- TNXP $42.63
- Analyst Decision
- CCIR
- TNXP Strong Buy
- Analyst Count
- CCIR 0
- TNXP 2
- Target Price
- CCIR N/A
- TNXP $585.00
- AVG Volume (30 Days)
- CCIR 457.2K
- TNXP 1.3M
- Earning Date
- CCIR 01-01-0001
- TNXP 08-15-2025
- Dividend Yield
- CCIR N/A
- TNXP N/A
- EPS Growth
- CCIR N/A
- TNXP N/A
- EPS
- CCIR 0.12
- TNXP N/A
- Revenue
- CCIR N/A
- TNXP $10,041,000.00
- Revenue This Year
- CCIR N/A
- TNXP $22.87
- Revenue Next Year
- CCIR N/A
- TNXP $711.66
- P/E Ratio
- CCIR $85.53
- TNXP N/A
- Revenue Growth
- CCIR N/A
- TNXP N/A
- 52 Week Low
- CCIR $9.92
- TNXP $6.76
- 52 Week High
- CCIR $13.35
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- CCIR N/A
- TNXP 52.35
- Support Level
- CCIR N/A
- TNXP $41.64
- Resistance Level
- CCIR N/A
- TNXP $50.39
- Average True Range (ATR)
- CCIR 0.00
- TNXP 3.99
- MACD
- CCIR 0.00
- TNXP -0.11
- Stochastic Oscillator
- CCIR 0.00
- TNXP 32.61
About CCIR COHEN CIRCLE ACQUISITION CORP I
Cohen Circle Acquisition Corp I is a blank check company.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.